--/10
Overview
Hims & Hers is the largest telehealth platform in the US, and they acquired a dedicated peptide manufacturing facility in 2025. On their February 2026 earnings call, they announced peptide product development. While their full peptide lineup hasn't launched yet, their entry into the market is expected to dramatically lower prices and normalize peptide therapy.
With their existing infrastructure, massive customer base, and manufacturing capabilities, Hims & Hers could become the dominant player in prescribed peptide therapy.
Key Details
Consultation: Free online consultation
Price Range: $199-299/month (GLP-1s)
Pharmacy: Own manufacturing facility + compounding pharmacies
Available In: All 50 states
Established: 2017
Peptides Available (2)
SemaglutideTirzepatide
Notable Features
- +Largest US telehealth platform
- +Owns peptide manufacturing facility (acquired 2025)
- +Expanding peptide lineup in 2026
- +Massive scale = lower prices
- +Free online consultations
- +Insurance partnerships developing
Strengths
- +Largest telehealth platform — trusted brand
- +Own manufacturing = quality control + lower costs
- +Available in all 50 states
- +Free consultations
Weaknesses
- -Limited peptide selection currently (GLP-1s only)
- -Full peptide lineup not yet launched
- -Less personalized than boutique clinics